share_log

Marijuana Company of America Appoints Marco Guerrero to new role as hempSMART Advisor Guerrero to Guide South American Distribution of hempSMART(TM) Products

Marijuana Company of America Appoints Marco Guerrero to new role as hempSMART Advisor Guerrero to Guide South American Distribution of hempSMART(TM) Products

美國大麻公司任命馬爾科·格雷羅擔任hempSMART顧問格雷羅,指導hempSMART(商標)產品在南美的分銷
Accesswire ·  2022/07/12 18:05

LOS ANGELES, CA / ACCESSWIRE / July 12, 2022 / Marijuana Company of America Inc. ("MCOA" or the "Company") (OTC PINK:MCOA), an innovative hemp and cannabis corporation, today announced the appointment of former director Marco Guerrero as special advisor to the Company's hempSMART™ South American division.

加利福尼亞州洛杉磯/ACCESSWIRE/2022年7月12日/ 美國大麻公司。("MCOA“或”公司)(場外交易市場代碼:MCOA),一家創新的大麻和大麻公司,今天宣佈任命前董事公司的馬爾科·格雷羅為公司的HempSMART™南美部的特別顧問。

MCOA's Latin American hempSMART™ joint venture currently serves medical users in Brazil, who buy hemp-derived CBD hempSMART™ products by prescription from Brazilian physicians. Brazil, a country with a population of over 212 million consumers, buys CBD in rapidly expanding quantities. MCOA intends to expand our consumer base by delivering more of our high-quality hempSMART™ product portfolio to Brazil and other Latin American countries.

MCoA在拉丁美洲的合資公司hempSMART™目前為巴西的醫療用户提供服務,這些用户通過巴西醫生的處方購買大麻衍生的cbd hempSMART™產品。擁有超過2.12億消費者的巴西,購買CBD的數量迅速增加。MCOA打算通過向巴西和其他拉美國家提供更多高質量的hempSMART™產品組合來擴大我們的消費者基礎。

Mr. Guerrero stepped down from MCOA's Board of Directors on July 1, 2022, to work with the Company as a non-executive advisor to our wholly-owned subsidiary Hempsmart Global, Inc., the parent company of MCOA's Latin American hempSMART™ joint venture. This new position will require him to focus exclusively on penetrating the Brazilian market. Consequently, there was a mutual agreement to have Marco step down as a director of MCOA.

格雷羅先生於2022年7月1日從MCOA董事會辭職,與公司一起工作,擔任我們的全資子公司HempSmart Global,Inc.的非執行顧問,HempSmart Global,Inc.是MCOA在拉丁美洲的HempSMART™合資企業的母公司。這一新職位將要求他專注於滲透巴西市場。結果,雙方達成協議,讓馬可辭去馬可在董事的職務。

Jesus M. Quintero, CEO, and CFO of MCOA stated, "Our joint venture in Brazil is building a solid base for our sales of hempSMART™ product line in Brazil and other significant South American markets, and is a major strategic partnership for MCOA. Brazil, with a sales potential of hundreds of millions of consumers, is central to our vision for expansion. While the US CBD market has matured and is saturated with brands, we believe there is an early market entrant advantage for us entering the market with our established hempSMART brand. Marco Guerrero is building out our South American framework and adding him as a special advisor to that MCOA division further aligns our focus on increasing sales in the region. We are focused on the opportunity for significant market penetration in the expanding Brazilian CBD market."

MCOA首席執行官兼首席財務官Jesse M.Quintero表示:“我們在巴西的合資企業為我們在巴西和其他重要的南美市場銷售hempSMART™產品系列奠定了堅實的基礎,也是MCOA的重要戰略合作伙伴關係。巴西擁有數億消費者的銷售潛力,是我們擴張願景的核心。雖然美國CBD市場已經成熟,品牌已經飽和,但我們相信,對於我們來説,憑藉我們成熟的hempSMART品牌進入市場具有早期的市場進入者優勢。Marco Guerrero正在建立我們的南美框架,並將他作為MCOA部門的特別顧問,進一步調整我們對增加該地區銷售的關注。我們專注於在不斷擴大的巴西中央商務區市場獲得重大市場滲透的機會。“

About Marijuana Company of America, Inc.

關於美國大麻公司。

MCOA is a corporation that participates in: (1) product research and development of legal hemp-based consumer products under the brand name "hempSMART™", which targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

MCoA是一家參與以下活動的公司:(1)“hempSMART™”品牌下合法大麻消費產品的產品研發,目標是大眾的健康和福祉;(2)關聯營銷計劃,以推廣和銷售其含有CBD的合法大麻消費產品;(3)隨着合法市場的成熟和發展,其業務擴展到合法大麻和大麻行業的輔助領域。

About Hempsmart Brazil

關於漢普斯馬特巴西

MCOA controls

MCOA控制

About our hempSMART Products Containing CBD

關於我們包含CBD的hempSMART產品

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is an effective treatment for any medical condition as drugs or dietary supplements subject to the FDA's jurisdiction.

美國食品和藥物管理局(FDA)尚未承認CBD是任何適應症的安全有效的藥物。我們的產品含有從工業大麻中提取的CBD,其銷售或銷售並不是基於將其用作受FDA管轄的藥物或膳食補充劑的任何醫療疾病的有效治療。

Forward-Looking Statements

前瞻性陳述

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

本新聞稿包含並非純粹歷史性的“前瞻性陳述”,可能包括有關對未來的信念、計劃、期望或意圖的任何陳述。此類前瞻性表述包括新商機的發展、成本和結果,以及諸如“預期”、“尋求”、“打算”、“相信”、“估計”、“預期”、“項目”、“計劃”等詞彙,或類似的表述可被視為1995年“私人證券訴訟改革法”所指的“前瞻性表述”。由於許多因素,實際結果可能與任何前瞻性陳述中預測的結果不同。這些因素包括與新項目相關的固有不確定性、未來美國和全球經濟、競爭的影響,以及該公司對現有法規的依賴,這些法規涉及大麻產品的使用和開發。這些前瞻性陳述是截至本新聞稿發佈之日作出的,我們沒有義務更新前瞻性陳述,也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的任何信念、計劃、預期和意圖都是合理的,但不能保證任何此類信念、計劃、預期或意圖將被證明是準確的。投資者應參考此處列出的所有信息,也應參考我們的年度報告Form 10-K、我們的Form 10-Q季度報告以及不時提交給美國證券交易委員會的其他定期報告中概述的風險因素披露。欲瞭解更多信息,請訪問Www.sec.gov.

CONTACT:

聯繫方式:

info@marijuanacompanyofamerica.com
info@mcoainvestments.com
888-777-4362

郵箱:info@marijuanacompanyofamerica.com
郵箱:Info@mcoainvestments.com
888-777-4362

SOURCE: Marijuana Company of America, Inc.

資料來源:美國大麻公司。


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論